Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1228 entries already.
Entries by Thomas Gabrielczyk
EU to decarbonise aviation sector through green fuel targets
/in News/by Thomas GabrielczykThe European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene.
Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
/in News/by Thomas GabrielczykIn 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated […]
Novartis in US$465m deal with 3B Pharmaceuticals GmbH
/in News/by Thomas GabrielczykTargeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Syngenta partners with Biotalys
/in News/by Thomas GabrielczykSyngenta has announced to leverage Biotalys AGROBODY technology platform to expand its biocontrol pipeline.
Phialogics AG bags pre-seed financing
/in News/by Thomas GabrielczykPhialogics AG has got a 600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.
Forbion raises 1.35bn across two funds
/in News/by Thomas GabrielczykEuropean life sciences venture capital company Forbion has raised two oversubscribed funds totalling 1.35 bn.
Ariceum Therapeutics extends Series A to 47.75m
/in News/by Thomas GabrielczykGerman radiopharmaceuticals developer Ariceum Therapeutics has raised a further 22.75m extension of its 25m Series A financing announced in June 2022.
Genmab and argenx combine antibody know-how
/in News/by Thomas GabrielczykGenmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.
Adaptyv Biosytems launches protein engineering foundry
/in News/by Thomas GabrielczykSwiss Adaptyv Biosystems Sàrl has launched two fast-feedback tools that allow cheap, rapid and minaturised validation of AI-designed proteins.